One thing that has helped to make progress against progressive supranuclear palsy, not as rare as KS, but still quite rare, is that it has properties that are i

One thing that has helped to make progress against progressive supranuclear palsy, not as rare as KS, but still quite rare, is that it has properties that are ideal for testing potential Alzheimers drugs. PSP patients have anomalous quantities of one of the two proteins that turn up in Alzheimers patients, so they are ideal for separating the effects of new therapies. So, a win-win emerges: PSP patients get well-funded clinical trials of therapies designed to address their affliction and the entire world gets improved understanding of therapies that target Alzheimers. If there is something special about KS that allows it to be a diagnostic for therapies in adjoining disease with broader impact, then suddenly an avenue opens for intense investment in therapies for KS.